Market News AIOpen the app

Incyte's drug povorcitinib is starting a Phase III trial in China for adults with non-segmental vitiligo.

TrialRead the original at briefingwire.com
Good for INCY

Dermavon has moved povorcitinib into Phase 3 testing under its exclusive China rights. This advances Incyte's program in a country with an estimated 8.2 million people with this form of vitiligo, but trial success is unproven.

INCY · Incyte Corporation

AI read · Good for INCY

The AI's read

This moves Incyte's drug program forward through its partner, which has exclusive rights in China. The trial targets a disease affecting an estimated 8.2 million people there, but it has not reported results. Success and any sales remain unproven.

Get alerts for INCY

Follow Incyte Corporation (INCY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for INCY
Free on the App Store and Google Play, or on the web.